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Abstract - Prostate cancer (PCa) is the second most commonly diagnosed cancer among men worldwide. Despite its high 
incidence rate, the molecular basis of PCa onset and its progression remains little understood. Genome-wide association 
studies (GWAS) have greatly contributed to the identification of single nucleotide polymorphisms (SNP) associated with 
PCa risk. Several GWAS identified 8q24 as one of the most significant PCa-associated regions. The aim of this study was to 
evaluate the association of SNP rs378854 at 8q24 with PCa risk in the Serbian population. The study population included 
261 individuals diagnosed with PCa, 257 individuals diagnosed with benign prostatic hyperplasia (BPH) and 106 healthy 
controls. Data quality analysis yielded results showing deviations from Hardy-Weinberg equilibrium in groups of PCa pa-
tients and BPH patients as well as in the control group. There was no significant association between alleles and genotypes 
of the genetic variant rs378854 and PCa risk in the Serbian population. 
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INTRODUCTION
Prostate cancer (PCa) is the second most commonly 
diagnosed malignant disease among men, and the 
sixth  leading  cause  of  cancer-related  death  in  the 
male population (Ferlay et al., 2010). The number of 
new cases of PCa diagnosed in the Serbian popula-
tion showed a 65% increase in the period between 
1999 and 2009, according to data obtained from cen-
tral Serbia (Vukičević et al., 2002; Miljuš et al., 2011). 
During this period, PCa remained the third most 
common cancer among males in the Serbian popula-
tion (Vukičević et al., 2002; Miljuš et al., 2011). Pre-
dictions made in the American population indicate 
that projected PCa incidence will increase by approx-
imately 45% from 2010 to 2030 (Smith et al., 2009). 
In the United Kingdom, the increase in number of 
diagnosed PCa from 2007 to 2030 was predicted to 
reach 69%, which would make this cancer the most 
common malignant disease in men (Mistry et al., 
2011). The only known risk factors for developing 
PCa, besides increasing age, are ethnic background 
and positive family history, which are considered to 
reflect the underlying genetic factors involved in PCa 
etiology (Hsing and Chokkalingam, 2006). 
As in other malignant diseases, the initiation and 
progression of PCa involve a progressive accumula-
tion of genetic and epigenetic alterations. Numerous 
chromosomal rearrangements and copy number al-
terations, along with somatic point mutations, have 
been associated with prostate carcinogenesis (Shen 476 G. BRAJUŠKOVIĆ ET AL.
and  Abate-Shen,  2010).  Furthermore,  global  and 
gene-specific changes in histone modifications and 
DNA  methylation  patterns  are  believed  to  be  in-
volved in PCa etiology (Li et al., 2005). 
Apart from these somatic alterations, numerous 
genetic polymorphisms have been identified as fac-
tors affecting the process of malignant transformation 
in prostatic tissue. Genome-wide association studies 
(GWAS) have greatly contributed to the identifica-
tion of single nucleotide polymorphisms associated 
with PCa risk (Amundadottir et al., 2006; Freedman 
et al., 2006; Gudmundsson et al., 2007a; Gudmunds-
son et al., 2007b; Haiman et al., 2007; Yeager et al., 
2007; Eeles et al., 2008; Gudmundsson et al., 2008; 
Thomas et al., 2008; Al Olama et al., 2009; Eeles et 
al., 2009; Gudmundsson et al., 2009; Yeager et al., 
2009; Takata et al., 2010). The first study of this type 
was performed in 2006 and led to the identification 
of association between several SNPs at 8q24 and PCa 
risk (Amundadottir et al., 2006). Afterwards, other 
loci in this region were identified as PCa susceptibil-
ity loci. Polymorphisms at 8q24 were also evaluated 
for association with the clinicopathological features 
of PCa. Several SNP showed significant association 
with a higher prostate-specific antigen (PSA) level at 
diagnosis, higher Gleason score, higher tumor stage, 
younger age at onset or greater disease aggressive-
ness in various populations (Armundadottir et al., 
2006; Zheng et al., 2007; Penney et al., 2009; Bao et 
al., 2010; Lange et al., 2012). 
The mechanism by which polymorphisms at 8q24 
affect PCa onset and progression remains largely un-
known. Since these polymorphisms reside within a 
region devoid of characterized protein-coding genes, 
a great effort has been made to evaluate the presence 
of transcribed sequences in this region, as well as the 
regulatory  sequences  of  adjacent  genes  (Huppi  et 
al., 2008; Pomerantz et al., 2009; Sotelo et al., 2010; 
Wasserman et al., 2010; Prensner et al., 2011; Ting et 
al., 2012). The closest annotated protein-coding genes 
are the family with sequence similarity 84, member 
B gene (FAM84B), and the proto-oncogene v-myc 
myelocytomatosis viral oncogene homolog (avian) 
(c-MYC). Somatic amplification of the chromosomal 
region  containing  MYC,  causing  its  overexpres-
sion, was detected in advanced and recurrent PCa 
(Jenkins et al., 1997). MYC protein was also found to 
be upregulated in prostatic intraepithelial neoplasia 
(PIN), suggesting its involvement in PCa initiation 
(Gurel et al., 2008). Evidence for this hypothesis was 
also obtained in a study that showed that MYC over-
expression is sufficient to drive normal human pro-
static epithelial cells to malignant phenotype within 
a tissue recombination model (Williams et al., 2005). 
Functional variants located within cis-regulatory ele-
ments of MYC could possibly underlay the observed 
association of numerous loci at 8q24 with PCa risk 
and aggressiveness by modifying its expression pat-
terns.  Findings  regarding  several  MYC  enhancers 
identified  at  8q24  in  the  intervals  associated  with 
PCa risk are supportive of this supposition (Sotelo 
et al., 2010; Wasserman, 2010; Ting et al., 2012). An-
other gene frequently amplified in PCa, along with 
MYC, is the plasmacytoma variant translocation 1 
(PVT1) oncogene, which encodes a long non-coding 
RNA (lincRNA) and is a host gene for several miR-
NAs whose functions are largely unknown (Meyer et 
al., 2011). A recent study conducted by Meyer et al. 
(2011) identified rs378854 as a novel functional vari-
ant associated with PCa risk. The G allele of rs378854 
was shown to reduce the binding of the Ying Yang 1 
(YY1) transcription regulator to the regulatory ele-
ment of PVT1, causing the increase in its expression 
but not influencing the expression of MYC (Meyer, 
2011). 
This study is the first to evaluate the possible as-
sociation of rs378854 with PCa risk in the Serbian 
population. It is also the first study to include the as-
sessment of the association between rs378854 and 
PCa progression in this population. 
MATERIALS AND METHODS
The study used peripheral blood samples obtained 
from patients treated in the period 2009-2012 at the 
Clinical Center “Dr Dragiša Mišović Dedinje” and 
Clinical Center “Zvezdara”. Research was conducted 
with the approval of the ethics committees of these 
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The  study  included  261  individuals  diagnosed 
with PCa and 257 individuals diagnosed with benign 
prostatic hyperplasia (BPH), who provided periph-
eral blood samples, as well as 106 healthy individu-
als comprising the control group from whom buccal 
swabs were obtained. The diagnoses of PCa and BPH 
were made using standard clinical procedure, which 
included digital rectal examination, transrectal ultra-
sonography, abdominal and pelvic ultrasound, bone 
scintigraphy and radiography, serum PSA level and 
biopsy of the prostate. Serum PSA levels were deter-
mined by the Hybritech method of monoclonal im-
munoassay. Information about the prostate-specific 
antigen serum level, Gleason score and clinical stage 
were available for individuals diagnosed with PCa. 
The clinical stage of cancer was determined accord-
ing to the TNM classification system. 
Patients diagnosed with PCa were classified into 
groups based on the values of standard prognostic 
parameters – PSA at diagnosis (PSA <10 ng/ml; 10 
ng/ml≤ PSA <20 ng/ml; PSA >20 ng/ml), Gleason 
score (GS <7; GS =7; GS >7) and clinical stage (T1; 
T2; T3/T4). The presence of metastases was an ad-
ditional parameter used for the classification of pa-
tients with PCa into two groups. Based on the risk of 
localized cancer progression, three groups of patients 
were formed according to D’Amico criteria (D’Amico 
et al., 1998). These groups were defined as low-risk 
(PSA <10 ng/ml, GS <6, and clinical stage T1-T2a), 
intermediate-risk  (PSA  10–20  ng/ml  or  GS  =7  or 
clinical stage T2b-T2c), and high-risk (PSA >20 ng/
ml or GS >7 or stage T3/T4) (D’Amico et al., 1998). 
Since patients with metastases were included in the 
study, the criteria were modified to include this sub-
set into the high-risk group. Patients were also se-
lected into the low-risk (Gleason score <7 and stage 
T1-T2) and high-risk (Gleason score ≥7 or stage T3/
T4 or metastases) groups according to Medeiros et 
al. (2002).
Genomic  DNA  was  isolated  from  peripheral 
blood and buccal swabs using QIAamp® DNA Mini 
Kit  (QIAGEN,  Hilden,  Germany)  following  the 
manufacturers’ protocol. The 303 bp of sequence sur-
rounding rs378854 was amplified by PCR from iso-
lated genomic DNA. Sequences of the primers used 
for PCR amplification are the following ones: forward 
primer - 5’-TCTGCAGATTCACAGCTCTTT-3’; re-
verse primer - 5’-AATGCCTCACCTTGCTTTG-3’. 
For the PCR step, forward primer was labeled at 5’ 
end with FAMTM. The PCR reaction mixture (final 
volume 15 µl per single reaction) contained 1.5 µl of 
10X PCR buffer A (with 15 mM MgCl2, Kapa Biosys-
tems, Woburn, MA, USA), dNTPs at final concen-
tration of 200 µM each (Fermentas, Hunover, MD, 
USA), primers at final concentration of 0.2 µM each 
(Applied Biosystems, Foster City, CA, USA), Taq DNA 
polymerase (Kapa Biosystems, Woburn, MA, USA) 
at final concentration of 0.04 U/µl, 2 µl of genom-
ic DNA (1-20 ng) and nuclease-free water (Serva, 
Westbury, NY, USA). The PCR thermocycling condi-
tions were as follows: 97oC for 3 min, followed by 35 
cycles of 95oC for 1 min, 60oC for 1 min and 72oC for 
1 min. Final extension was performed at 72oC for 10 
min, after which the reaction mixture was incubated 
at 20oC for 20 min. 
PCR products (3.33 µl) were digested with 1 U of 
restriction enzyme MspI (HpaII) (Fermentas, Huno-
ver, MD, USA) for 24 h in a reaction volume of 5 µl, 
which also included 0.5 µl of 10X buffer R (Fermen-
tas,  Hunover,  MD,  USA)  and  nuclease-free  water 
(Serva, Westbury, NY, USA). Digestion of the PCR 
products with MspI resulted in the formation of a 
different set of fragments depending on the rs378854 
genotype (GG: 113 bp, 88 bp, 66 bp and 36 bp; GA: 
149 bp, 113 bp, 88 bp, 66 bp and 36 bp; AA: 149 bp, 
88 bp and 66 bp).
The  loading  mixture  for  gel  electrophoresis 
which included 8.7 µl of Hi-Di formamide (Applied 
Biosystems,  Foster  City,  CA,  USA)  and  0.3  µl  of 
Gene Scan 500 Liz Size Standard (Applied Biosys-
tems, Foster City, CA, USA) was mixed with 1.1 µl 
of restriction digestion product. Samples were de-
naturized at 95oC for 5 min. Fragments were sepa-
rated by capillary gel electrophoresis using a 3130 
Genetic analyzer (Applied Biosystems, Foster City, 
CA, USA). The results of electrophoresis were ana-
lyzed by GeneMapper (Applied Biosystems, Foster 
City, CA, USA). The detected fragment length for 478 G. BRAJUŠKOVIĆ ET AL.
the rs378854 GG genotype was 113 bp. For the GA 
genotype fragment, lengths were 149 bp and 113 bp, 
while for the AA genotype the detected fragment 
was 149 bp long.
Statistical  analysis  of  SNP  association  was  per-
formed using PLINK statistical software (Purcell et 
al., 2007). Hardy-Weinberg equilibrium (HWE) was 
assessed using the exact test (Wigginton et al., 2005) 
implemented in PLINK. The Cochran-Armitage trend 
test was used to assess the association of rs378854 with 
PCa risk and progression under an additive genetic 
model. The odds ratio (OR) was calculated as a meas-
ure of the effect size of G allele. A 5% level of signifi-
cance was used in the analysis.
RESULTS
The genotyping of rs378854 was successful in the 106 
control subjects, 257 patients with BPH and 261 pa-
tients with PCa. Clinical and pathological features of 
the group of patients diagnosed with PCa are shown 
in Table 1. The majority of subjects had an elevated 
serum PSA over 20 ng/µl, while less than 15% of sub-
jects had a high Gleason score. About 30% of patients 
had advanced stage PCa. In addition, most of the pa-
tients were diagnosed with high-risk PCa according 
to both D’Amico criteria (D’Amico et al., 1998) and 
Medeiros et al. (2002) (Table 2). 
The allele and genotype frequencies of rs378854 
in the groups of patients diagnosed with PCa and 
BPH, as well as in the control group, are shown in 
Table 3. The frequencies of rs378854 genotypes were 
inconsistent with HWE between both groups of pa-
tients with PCa and BPH as well as among the con-
trols (results not shown). Due to this observation, a 
statistical method that does not assume HWE was 
Table 1. Classification of patients with prostate cancer based on values of standard prognostic parameters regarding disease progres-
sion.
Standard prognostic parameter
Prostate cancer patients
n (%)
PSA at diagnosis
<10 ng/ml 81 (31.3)
10-20 ng/ml 68 (26.2)
>20 ng/ml 110 (42.5)
Unknown 2
Gleason score
<7 145 (57.5)
=7 72 (28.6)
>7 35 (13.9)
Unknown 9
Clinical stage
T1 40 (18.2)
T2 113 (51.4)
T3/T4 67 (30.4)
Unknown 41
Metastases
Detected 72 (32.7)
Not detected 148 (67.3)
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used  to  test  the  possible  association  of  rs378854 
with PCa risk (Table 4). No significant association 
of rs378854 with PCa risk was determined in com-
paring genotype distributions in patients with PCa 
and controls. Comparison of genotype distributions 
among the patients with PCa and BPH also yielded 
no  evidence  of  association  between  rs378854  and 
PCa  risk.  Furthermore,  no  significant  association 
was observed between rs378854 and the risk of BPH 
(Table 4).
The frequencies of rs378854 A allele and geno-
type distributions in the groups of patients formed 
according to the values of standard prognostic pa-
rameters regarding the progression of PCa and the 
risk of progression assessed according to D’Amico 
et al. (1998) and Medeiros et al. (2002), are sum-
marized in Table 5 and Table 6, respectively. Due to 
deviations from HWE, the Pearson chi-square test 
could not be used to analyze 3x3 contingency tables. 
For this reason, differences between the groups of 
patients formed according to the values of standard 
prognostic parameters of PCa progression were ana-
lyzed using the Cochran-Armitage trend test on 2x3 
contingency tables. These tests showed no evidence 
of the supposed association (Table 7). Also, no statis-
tically significant association between rs378854 and 
the presence of metastases was determined (Table 
Table 2. Classification of patients with prostate cancer based on risk of disease progression.
Risk group
Prostate cancer patients
n (%)
D’Amico risk criteria
Low-risk 16 (6.4)
Intermediate-risk 87 (34.9)
High-risk 146 (58.6)
Unknown 12
Medeiros et al. risk criteria
Low-risk 96 (40.3)
High-risk 142 (59.7)
Unknown 23
Table 3. rs378854 A allele frequencies and genotype distributions in groups of patients with prostate cancer, benign prostatic hyperpla-
sia and in the control group.
Group Allele A frequency
Genotype frequencies
GG GA AA
Prostate cancer 0.278 0.444 0.341 0.215
Benign prostatic hyperplasia 0.264 0.471 0.327 0.202
Controls 0.302 0.396 0.349 0.255
Table 4. Association of G allele and genotypes of rs378854 with prostate cancer risk.
Comparison P value Per allele OR (95% CI)
PCa vs. BPH 0.527 0.92 (0.72-1.18)
PCa vs. controls 0.328 1.20 (0.87-1.66)
BPH vs. controls 0.160 1.30 (0.94-1.81)
Abbreviations: OR-odds ratio; CI-confidence interval.480 G. BRAJUŠKOVIĆ ET AL.
7). Similar results were obtained in analysis of the 
association between rs378854 and the risk of PCa 
progression.  Differences  in  genotype  frequencies 
between the groups of patients formed according to 
D’Amico criteria (D’Amico et al., 1998) did not reach 
statistical significance (Table 8). The results of the ap-
plied statistical tests also provided no evidence for 
an association of rs378854 with the risk of PCa pro-
gression assessed according to Medeiros et al. (2002) 
(Table 8). 
DISCUSSION
Over the past decade, GWAS have had substantial 
success in identifying genetic variants associated with 
complex diseases. The first GWAS of PCa yielded evi-
dence of an association between the genetic variant at 
8q24 and the risk of developing prostate malignancy 
(Amundadottir et al., 2006). Since then, five differ-
ent regions within the 8q24 gene desert have been 
reported by GWAS to be associated with PCa risk, 
of which some also confer the risk of breast, ovarian, 
colorectal or bladder cancer (Ghoussaini et al., 2008; 
Wasserman et al., 2010). Molecular mechanisms un-
derlying the association of variants within 8q24 with 
different malignant diseases are still largely unknown. 
Several lines of evidence suggest a possible effect of 
SNP at 8q24 on MYC gene expression (Ahmadiyeh 
et al., 2010; Wasserman et al., 2010). MYC was found 
to be upregulated in both prostate and breast tumor 
Table 5. rs378854 A allele frequencies and genotype distributions in groups of patients with prostate cancer formed according to values 
of standard prognostic parameters. 
Comparison Allele A frequency
Genotype frequencies
GG GA AA
PSA at diagnosis
<10 ng/ml 0.426 0.407 0.333 0.259
10-20 ng/ml 0.397 0.412 0.382 0.206
>20 ng/ml 0.350 0.491 0.318 0.191
Gleason score
<7 0.369 0.448 0.366 0.186
=7 0.423 0.458 0.236 0.306
>7 0.386 0.371 0.486 0.143
Clinical stage
T1 0.388 0.425 0.375 0.200
T2 0.403 0.416 0.363 0.221
T3/T4 0.328 0.507 0.328 0.164
Metastases
Detected 0.354 0.486 0.319 0.194
Not detected 0.388 0.425 0.372 0.203
Table 6. rs378854 A allele frequencies and genotype distributions in groups of patients formed according to criteria for assessment of 
the risk of prostate cancer progression described by D’Amico et al. (1998) and Medeiros et al. (2002).
Group Allele A frequency
Genotype frequencies
GG GA AA
D’Amico et al. (1998) risk criteria
Low-risk 0.344 0.438 0.438 0.125
Intermediate-risk 0.431 0.391 0.356 0.253
High-risk 0.356 0.486 0.315 0.199
Medeiros et al. (2002) risk criteria
Low-risk 0.385 0.427 0.375 0.198
High-risk 0.387 0.451 0.324 0.225SNP rs378854 AND PROSTATE CANCER RISK 481
samples and is thought to be implicated in PCa initi-
ation, as well as in the progression of disease (Jenkins 
et al., 1997; Bièche et al., 1999; Gurel et al., 2008). 
FAM84B, a nearby gene, has also been proposed to 
be a PCa susceptibility gene. FAM84B was shown to 
be overexpressed in PCa, mainly in the early stages, 
and is suggested to be a target of somatic amplifica-
tion (Solé et al., 2008). A processed pseudogene POU 
class 5 homeobox 1B (POU5F1B) located at 8q24 
was also found to be significantly overexpressed in 
PCa compared to surrounding normal prostatic tis-
sue (Kastler et al., 2010). Reported overexpression 
in PCa and its homology with the octamer-binding 
transcription factor 4 (OCT4) gene involved in the 
maintenance of the pluripotency of stem cells qualify 
POU5F1B as a plausible PCa susceptibility candidate 
gene  (Kastler  et  al.,  2010).  Recently,  several  non-
coding RNA genes have been identified at 8q24 and 
considered for possible involvement in prostate car-
cinogenesis. Altered expression patterns in PCa and/
or PIN have been shown for lincRNA genes, such as 
PVT1, prostate cancer non-coding RNA 1 (PRNCR1) 
and prostate cancer associated transcript 1 (PCAT1), 
while  for  microRNA  (miRNA)-coding  genes  such 
results have not yet been obtained (Kim et al., 2007; 
Pomerantz et al., 2009; Chung et al., 2011; Meyer et 
al., 2011; Prensner et al., 2011). 
A study by Meyer et al. (2011) showed a signifi-
cant association between PCa risk and the functional 
Table 7. Association of rs378854 with standard prognostic parameters regarding prostate cancer progression and the presence of me-
tastases.
Comparison P value Per allele OR (95% CI)
PSA at diagnosis
10-20 ng/ml vs. <10 ng/ml 0.654 1.13 (0.71-1.79)
>20 ng/ml vs. <10 ng/ml 0.188 1.38 (0.91-2.09)
>20 ng/ml vs. 10-20 ng/ml 0.426 1.22 (0.79-1.90)
Gleason score
=7 vs. <7 0.338 0.80 (0.53-1.20)
>7 vs. <7 0.810 0.93 (0.54-1.59)
>7 vs. =7 0.648 1.17 (0.65-2.10)
Clinical stage
T2 vs. T1 0.831 0.94 (0.56-1.58)
T3/T4 vs. T1 0.431 1.29 (0.73-2.30)
T3/T4 vs. T2 0.209 1.38 (0.88-2.16)
Metastases
Detected vs. Not detected 0.532 1.16 (0.77-1.75)
Abbreviations: OR-odds ratio; CI-confidence interval.
Table 8. Association of rs378854 with the risk of prostate cancer progression assessed according to D’Amico et al. (1998) and Medeiros 
et al. (2002).
Comparison P value Per allele OR (95% CI)
D’Amico et al. (1998) risk criteria
Intermediate-risk vs. Low-risk 0.409 0.69 (0.31-1.52)
High-risk vs. Low-risk 0.902 0.95 (0.44-2.04)
High-risk vs. Intermediate-risk 0.159 1.37 (0.93-2.01)
Medeiros et al. (2002) risk criteria
High-risk vs. Low-risk 0.970 0.99 (0.68-1.45)
Abbreviations: OR-odds ratio; CI-confidence interval.482 G. BRAJUŠKOVIĆ ET AL.
variant  rs378854,  which  confers  increased  expres-
sion of PVT1. The G allele of rs378854 reduces the 
binding of the YY1 transcription repressor to the 
regulatory element within 8q24 that was shown to 
affect the expression of PVT1, but not the adjacent 
MYC gene. These findings were reported for both 
European-Americans and African-Americans, even 
though  risk  allele  frequencies  differ  significantly 
between these ethnic groups. There was also no evi-
dence of rs378854 affecting the expression patterns 
of  miRNAs  hosted  within  the  PVT1  gene  (Meyer 
et al., 2011). Furthermore, the expression on hsa-
mir-1208, a miRNA located downstream of PVT1, 
was also found to be affected by the rs378854 geno-
type (Meyer et al., 2011).
Our study evaluated the possible association be-
tween rs378854 and PCa risk and progression in the 
Serbian population. Due to the observed deviation 
from HWE in both groups of patients with PCa and 
BPH, as well as in the control group, the results were 
examined for miscalling genotypes that showed no 
obvious errors in the genotyping procedure. Further 
reasonable  explanations  for  the  discordance  with 
HWE include possible duplications creating pseudo-
SNPs (Leal, 2005). Apart from duplication, deletion 
polymorphisms in the amplified region could influ-
ence the genotyping results causing a misinterpreta-
tion of heterozygotes as homozygotes (Balding, 2006). 
Other factors with possible influence on the devia-
tions from HWE are natural selection and genetic 
drift, as well as population admixture and inbreeding 
(Schaid and Jacobsen, 1999; Balding, 2006).
In contrast to the results of Meyer et al. (2011), 
our  study  showed  no  evidence  of  association  be-
tween rs378854 and PCa risk. This SNP was identi-
fied as a functional genetic variant in perfect LD with 
the previously reported a PCa susceptibility variant 
rs620861 (heterozygote OR = 1.17, 95% CI 1.10-1.24; 
homozygote OR = 1.33, 95% CI 1.21-1.45) (Meyer, 
2011;  Yeger,  2009).  Association  between  rs620861 
and  PCa  risk  was  found  in  a  GWAS.  It  involved 
10,286 PCa cases and 9,135 controls of European an-
cestry (Yeger, 2009). Therefore, the small sample size 
compared to the number of subjects involved in the 
previous study could influence the results obtained in 
the Serbian population and underlie the lack of rep-
lication of GWAS results. Considering the observed 
HWE deviations, the discordance of our results with 
those previously reported could also be due to popu-
lation characteristics, aside from methodological er-
rors and genetic alterations (Balding, 2006; Schaid 
and Jacobsen, 1999). 
Analysis of the effect of the rs378854 G allele on 
PCa progression yielded no evidence to support the 
supposed  association.  These  data  concur  with  the 
results obtained in the studies by Al Olama et al. 
(2009) and Lindstrom et al. (2011) that showed no 
evidence of association of rs620861 (in perfect LD 
with rs378854) with tumor grade and stage. Anoth-
er result of the study conducted by Al Olama et al. 
(2009) is a weak association of rs620861 with PSA 
level, which was not confirmed in our analysis in-
volving rs378854. Furthermore, Klein et al. (2012) 
showed  no  evidence  for  the  association  between 
rs620861 and PCa aggressiveness as evaluated under 
three different definitions.
Further  conclusions  about  an  association  be-
tween rs378854 and PCa in the Serbian population 
cannot be made without a final exclusion of genotyp-
ing error by retyping the SNP using different meth-
odology, preferably bidirectional sequencing. A larg-
er number of subjects will be required to determine 
if sample size affects the observed results.
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